Service
Weight medicine — medically supervised obesity therapy
Structured medical support for obesity and overweight with comorbidities — diagnostics, lifestyle strategy and, on clear indication, medicinal support with GLP-1 or incretin therapy.
Obesity is a chronic, multifactorial condition — not simply a matter of discipline. Effective therapy combines nutrition, exercise, behavioural support and — where indicated — medicinal components under medical supervision. The indication for medicinal support is set individually based on BMI, comorbidities and risk profile.
Book an appointment
Weight medicine appointment
I look forward to advising you personally. Book online in a few clicks or send a quick question.
Hunger and satiety are hormonally regulated — in many people with overweight this system is shifted. Modern medicinal options act here: GLP-1 receptor agonists (active substances semaglutide and liraglutide) and the combined GLP-1/GIP agonist tirzepatide reinforce the body's own satiety signals, slow gastric emptying and — when used correctly — can enable meaningful weight reduction.
Three active substances are available in Austria: semaglutide and liraglutide (GLP-1 receptor agonists — approved both for type 2 diabetes mellitus and, in higher dosing, for obesity therapy) and tirzepatide (combined GLP-1/GIP agonist, approved for type 2 diabetes and for weight management). Which substance fits in an individual case is decided after diagnostics and informed consent on effect, possible side effects and contraindications.
The injection alone is not the solution. Sustainable weight reduction emerges from the interplay with nutrition, exercise, sleep and behavioural strategies — this support is part of the therapy and is structured in follow-up appointments. When discontinuing the medication without lifestyle adjustment, partial weight regain is to be expected.
Treatment building blocks
- Medical history and status (BMI, waist circumference, comorbidities, prior attempts)
- Laboratory diagnostics: HbA1c, lipid profile, thyroid, liver and kidney values, hormone status where indicated
- Individual treatment plan — nutrition, exercise, behaviour
- Medicinal support where indicated: GLP-1 receptor agonists (semaglutide, liraglutide), GLP-1/GIP agonist tirzepatide
- Informed consent on effect, possible side effects, contraindications and realistic expectations
- Follow-up appointments with weight and laboratory course, therapy adjustment
- Integration with nutritional, sports and pain medicine (e.g. knee osteoarthritis, sleep apnoea, migraine with metabolic component)
At a glance
- Indication: BMI ≥ 30, or ≥ 27 with a comorbidity
- First consultation 60 minutes plus laboratory diagnostics
- Medicinal options: GLP-1 and incretin therapy
- Private practice service — medication on private prescription
When medical support is useful
- Obesity (BMI ≥ 30 kg/m²)
- Overweight (BMI ≥ 27 kg/m²) with at least one comorbidity — type 2 diabetes or pre-diabetes, hypertension, dyslipidaemia, sleep apnoea, non-alcoholic fatty liver disease, joint-loading conditions
- Repeated unsuccessful weight attempts despite lifestyle adjustments
- Type 2 diabetes mellitus with overweight
- Planned surgery where weight reduction lowers peri-operative risk
Procedure flow
- 1First consultation 60 minutes: history, prior findings, life situation, expectations
- 2Laboratory and, where indicated, additional diagnostics
- 3Findings review with individual treatment plan; on indication, private prescription and informed consent on use
- 4Follow-up consultations 30 minutes for therapy guidance, lifestyle support and tolerability
- 5Where needed: handover or integration with endocrinology, obesity surgery, nutritional or sports medicine
Important notes
- This therapy is not a quick fix. Effect and tolerability vary individually; a success guarantee cannot be given.
- Lifestyle components (nutrition, exercise, sleep) remain the foundation. Without them, a lasting effect is unlikely.
- Contraindications are checked at the first consultation — including medullary thyroid carcinoma (including in family history), MEN-2 syndrome, severe pancreatitis history, pregnancy and breastfeeding.
- Possible side effects — mainly gastrointestinal (nausea, fullness, vomiting), more rarely pancreatitis or gallstone-related complications — are discussed in detail.
- Medication costs are borne by the patient (private prescription). Statutory-insurance reimbursement for the obesity indication is generally not provided in Austria.
Book an appointment
Weight medicine appointment
I look forward to advising you personally. Book online in a few clicks or send a quick question.
Private practice (Wahlarzt). Private practice with no statutory health-insurance contracts. You receive an invoice that may be submitted to your insurer for partial reimbursement.